* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4...
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patient...
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinic...
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary ...
* Two-year research collaboration to develop new reactive group chemistries targeting non-cystein...
* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seek...
* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via ...
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced to...
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealan...
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clin...